I think part of the challenge is no one wants to throw their hands up in the air and abandon amyloid after so many years and dollars spent on it. Instead, they say "well we just weren't doing an early enough intervention", which is how Aducanumab was forced through with weak evidence of effectiveness.

The big question is what do we do now? There's Tau, but that hasn't been a slam dunk either.